Remdesivir use and outcomes during the FDA COVID-19 emergency use authorization period

Remdesivir use and outcomes during the FDA COVID-19 emergency use authorization period

Background: Remdesivir (RDV) was approved for treatment of coronavirus disease 2019 (COVID-19), in May 2020 under US Food and Drug Administration emergency use authorization (EUA). Clinical outcomes related to RDV use in hospitalized patients during the EUA period are not well described. Methods: We...

Full description

Bibliographic Details
Main Authors: Ramy H. Elshaboury, Miranda M. Monk, Lisa M. Bebell, Monique R. Bidell, Meagan L. Adamsick, Ronak G. Gandhi, Molly L. Paras, Elizabeth L. Hohmann, Alyssa R. Letourneau
Format: Article
Language:English
Published: SAGE Publishing 2021-09-01
Series:Therapeutic Advances in Infectious Disease
Online Access:https://doi.org/10.1177/20499361211046669

Internet

https://doi.org/10.1177/20499361211046669

Similar Items